.grx-pd { max-width: 760px; font-family: -apple-system, BlinkMacSystemFont, "Segoe UI", Roboto, Helvetica, Arial, sans-serif; color: #1a1a1a; line-height: 1.5; } .grx-pd__intro { font-size: 1em; margin: 0 0 1.75rem; } .grx-pd__intro strong { color: #0f0f0f; } .grx-pd__grid { display: grid; grid-template-columns: repeat(auto-fit, minmax(260px, 1fr)); gap: 14px; margin: 0 0 2rem; } .grx-pd__card { background: #f7f8fa; color: #3d3d3d; border-radius: 0; padding: 16px 18px; font-size: 1em; transition: box-shadow .15s ease, transform .15s ease; } .grx-pd__card:hover { box-shadow: 0 4px 14px rgba(0,0,0,.06); } .grx-pd__card-title { display: block; font-size: 1em; font-weight: 700; color: #0f0f0f; margin: 0 0 .5rem; line-height: 1.5; } .grx-pd__legal { border-top: 1px solid #e6e8ec; padding-top: 1.5rem; font-size: 1em; color: #6b7280; line-height: 1.55; } .grx-pd__legal p { margin: 0 0 .6rem; font-size: 1em;} .grx-pd__legal p:last-child { margin-bottom: 0; } ARA-290 (also known as cibinetide) is a synthetic, non-hematopoietic peptide derived from the helix B domain of erythropoietin (EPO). It is designed to selectively interact with the innate repair receptor (IRR), a heteromeric complex comprising the erythropoietin receptor and the beta-common receptor (CD131). By engaging this specific receptor complex, ARA-290 supports tissue-protective signaling pathways without stimulating erythropoiesis, making it suitable for targeted modulation of inflammatory and reparative processes. Innate Repair Receptor ActivationARA-290 selectively activates the innate repair receptor (IRR) to support tissue protection and cellular resilience. Neuroinflammation ModulationARA-290 has been evaluated in peer-reviewed literature for its role in modulating neuroinflammation and supporting nerve fiber regeneration in preclinical models. Anti-Inflammatory SignalingARA-290 is associated with the downregulation of pro-inflammatory cytokines and the dampening of inflammatory immune-cell recruitment. Anti-Apoptotic PropertiesARA-290 demonstrates anti-apoptotic properties by inhibiting cellular death signaling pathways in tissue injury models. Cytoprotective & Neuroprotective EffectsARA-290 provides the cytoprotective and neuroprotective benefits associated with erythropoietin signaling while avoiding the hematopoietic effects of classical EPO receptor activation. This product is intended for use by licensed healthcare providers in clinical settings. It is not intended for consumer sale. Buyer/doctor has determined and documented that the use of this product is appropriate for the patient based on the assessment of the patient's needs. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. For professional use only.
Related
Related